Lansoprazole: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
 
(6 intermediate revisions by the same user not shown)
Line 5: Line 5:
|drugClass=gastrointestinal, anti-ulcer agent
|drugClass=gastrointestinal, anti-ulcer agent
|indicationType=treatment
|indicationType=treatment
|hasBlackBoxWarning=Yes
|indication=[[duodenal ulcer disease]], [[erosive esophagitis]], erosive esophagitis- maintanance, short-term treatment of active [[gastric ulcer]], gastric ulcer - NSAID-associated gastropathy, [[gastroesophageal reflux disease]], [[Zollinger-Ellison syndrome]] and for prophylaxis of gastric ulcer
|adverseReactions=<!--Black Box Warning-->
|adverseReactions=[[abdominal pain]], [[constipation]], [[diarrhea]], [[nausea]], [[headache]]
|blackBoxWarningTitle=Title
|blackBoxWarningTitle=Title
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
Line 19: Line 19:
* Dosing Information
* Dosing Information


:* Dosage
:*Helicobacter pylori gastrointestinal tract infection, Dual therapy: dual therapy is not recommended due to the increasing resistance rates in Helicobacter pylori infections


=====Duodenal ulcer disease, Short-term treatment of active disease and maintenance of healed ulcers=====
=====Duodenal ulcer disease, Short-term treatment of active disease and maintenance of healed ulcers=====
Line 25: Line 25:
* Dosing Information
* Dosing Information


:* Dosage
:*Treatment of active ulcer, 15 mg ORALLY once daily up to 4 weeks
 
:*Maintenance of healed ulcer, 15 mg ORALLY once daily


=====Duodenal ulcer disease, Triple therapy - Helicobacter pylori gastrointestinal tract infection, Triple therapy=====
=====Duodenal ulcer disease, Triple therapy - Helicobacter pylori gastrointestinal tract infection, Triple therapy=====
Line 31: Line 33:
* Dosing Information
* Dosing Information


:* Dosage
:* 30 mg ORALLY twice daily in combination with amoxicillin 1 gram ORALLY twice daily and clarithromycin 500 mg ORALLY twice daily for 10 to 14 days


=====Erosive esophagitisView additional information.=====
:*30 mg ORALLY twice daily in combination with metronidazole 500 mg ORALLY twice daily and clarithromycin 500 mg ORALLY twice daily for 10 to 14 days
 
=====Erosive esophagitis=====


* Dosing Information
* Dosing Information


:* Dosage
:*30 mg ORALLY once daily for 8 to 16 weeks; another 8 weeks for recurrence may be considered


=====Erosive esophagitis, Maintenance=====
=====Erosive esophagitis, Maintenance=====
Line 43: Line 47:
* Dosing Information
* Dosing Information


:* Dosage
:* 15 mg ORALLY once daily


=====Gastric ulcer, short-term treatment of active ulcerView additional information.=====
=====Gastric ulcer, short-term treatment of active ulcer=====


* Dosing Information
* Dosing Information


:* Dosage
:*30 mg ORALLY once daily up to 8 weeks


=====Gastric ulcer; Prophylaxis - NSAID-associated gastropathy=====
=====Gastric ulcer; Prophylaxis - NSAID-associated gastropathy=====
Line 55: Line 59:
* Dosing Information
* Dosing Information


:* Dosage
:*15 mg ORALLY once daily up to 12 weeks


=====Gastric ulcer - NSAID-associated gastropathy, Treatment=====
=====Gastric ulcer - NSAID-associated gastropathy, Treatment=====
Line 61: Line 65:
* Dosing Information
* Dosing Information


:* Dosage
:*30 mg ORALLY once daily for 8 weeks


=====Gastroesophageal reflux disease=====
=====Gastroesophageal reflux disease=====
Line 67: Line 71:
* Dosing Information
* Dosing Information


:* Dosage
:*15 mg ORALLY once daily up to 8 weeks


=====Zollinger-Ellison syndrome=====
=====Zollinger-Ellison syndrome=====
Line 73: Line 77:
* Dosing Information
* Dosing Information


:* Dosage
:*60 mg ORALLY once daily up to 90 mg twice daily




Line 80: Line 84:


<!--Guideline-Supported Use (Adult)-->
<!--Guideline-Supported Use (Adult)-->
|offLabelAdultGuideSupport======Condition1=====
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Lansoprazole in adult patients.
 
|offLabelAdultNoGuideSupport======Duodenal ulcer disease, Quadruple therapy - Helicobacter pylori gastrointestinal tract infection, Quadruple therapy=====
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:


* Dosing Information
* Dosing Information


:* Dosage
:* Helicobacter pylori gastrointestinal tract infection, Quadruple therapy: (quadruple therapy) lansoprazole 30 mg ORALLY twice daily, metronidazole 250 mg ORALLY four times a day, bismuth subsalicylate 525 mg ORALLY four times a day and tetracycline 500 mg ORALLY four times a day for 10 to 14 days


=====Condition2=====
=====Gastric ulcer, Maintenance=====


There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.


<!--Non–Guideline-Supported Use (Adult)-->
====Heartburn====
|offLabelAdultNoGuideSupport======Duodenal ulcer disease, Quadruple therapy - Helicobacter pylori gastrointestinal tract infection, Quadruple therapy=====


* Dosing Information
* Dosing Information


:* Dosage
:*15 mg ORALLY once a day for 14 days
 
=====Gastric ulcer, Maintenance=====
Heartburn
 
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.


<!--Pediatric Indications and Dosage-->
<!--Pediatric Indications and Dosage-->


<!--FDA-Labeled Indications and Dosage (Pediatric)-->
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
Barrett's esophagusView additional information.    Duodenal ulcer disease, Quadruple therapy - Helicobacter pylori gastrointestinal tract infection, Quadruple therapyView additional information.
    Gastric ulcer, MaintenanceView additional information.
    HeartburnView additional information.
|fdaLIADPed======Erosive esophagitis(1 yr and older)=====
|fdaLIADPed======Erosive esophagitis(1 yr and older)=====


* Dosing Information
* Dosing Information


:* Dosage
:*1 to 11 years of age, weight 30 kg or less, 15 mg ORALLY once daily for up to 12 weeks, may increase dose up to 30 mg twice daily if symptoms persist after 2 or more weeks of treatment


=====Gastroesophageal reflux disease ( 1 year and older (oral formulation))=====
:* 1 to 11 years of age, weight more than 30 kg, 30 mg ORALLY once daily for up to 12 weeks, may increase dose up to 30 mg twice daily if symptoms persist after 2 or more weeks of treatment
|offLabelPedGuideSupport======Condition1=====


* Developed by:
:*12 years of age and older, 30 mg ORALLY once daily for up to 8 weeks


* Class of Recommendation:
=====Gastroesophageal reflux disease ( 1 year and older (oral formulation))=====


* Strength of Evidence:
** Dosing Information


* Dosing Information
:*1 to 11 years of age, weight greater than 30 kg, 30 mg ORALLY once daily for up to 12 wk, may increase dose up to 30 mg twice daily if symptoms persist after 2 or more weeks of treatment


:* Dosage
:*12 years of age and older, 15 mg once daily for up to 8 weeks
 
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Lansoprazole in pediatric patients.
=====Condition2=====
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Lansoprazole in pediatric patients.
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Non–Guideline-Supported Use (Pediatric)-->
|offLabelPedNoGuideSupport======Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Contraindications-->
|contraindications=* Condition1
|contraindications=* Condition1


Line 160: Line 129:
Do not use
Do not use


    if you have trouble or pain swallowing food, vomiting with blood, or bloody or black stools. These may be signs of a serious condition. See your doctor.  
*if you have trouble or pain swallowing food, vomiting with blood, or bloody or black stools. These may be signs of a serious condition. See your doctor.  


Ask a doctor before use if you have
Ask a doctor before use if you have


    liver disease  
*liver disease  
    had heartburn over 3 months. This may be a sign of a more serious condition.  
*had heartburn over 3 months. This may be a sign of a more serious condition.  
    heartburn with lightheadedness, sweating or dizziness  
*heartburn with lightheadedness, sweating or dizziness  
    chest pain or shoulder pain with shortness of breath; sweating; pain spreading to arms, neck or shoulders; or lightheadedness  
*chest pain or shoulder pain with shortness of breath; sweating; pain spreading to arms, neck or shoulders; or lightheadedness  
    frequent chest pain  
*frequent chest pain  
    frequent wheezing, particularly with heartburn  
*frequent wheezing, particularly with heartburn  
    unexplained weight loss  
*unexplained weight loss  
    nausea or vomiting  
*nausea or vomiting  
    stomach pain  
*stomach pain  


Ask a doctor or pharmacist before use if you are taking
Ask a doctor or pharmacist before use if you are taking


    warfarin (blood-thinning medicine)  
*warfarin (blood-thinning medicine)  
    prescription antifungal or anti-yeast medicines  
*prescription antifungal or anti-yeast medicines  
    digoxin (heart medicine)  
*digoxin (heart medicine)  
    theophylline (asthma medicine)  
*theophylline (asthma medicine)  
    tacrolimus (immune system medicine)  
*tacrolimus (immune system medicine)  
    atazanavir (medicine for HIV infection)  
*atazanavir (medicine for HIV infection)  


Stop use and ask a doctor if
Stop use and ask a doctor if


    your heartburn continues or worsens  
*your heartburn continues or worsens  
    you need to take this product for more than 14 days  
*you need to take this product for more than 14 days  
    you need to take more than 1 course of treatment every 4 months  
*you need to take more than 1 course of treatment every 4 months  
    you get diarrhea  
*you get diarrhea  


If pregnant or breast-feeding,
If pregnant or breast-feeding,


ask a health professional before use.
*ask a health professional before use.


Keep out of reach of children.
Keep out of reach of children.


In case of overdose, get medical help or contact a Poison Control Center right away. (1-800-222-1222)
*In case of overdose, get medical help or contact a Poison Control Center right away. (1-800-222-1222)
|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
 
=====Body as a Whole=====
 
 
 
 
=====Cardiovascular=====
 
 
 
 
=====Digestive=====
 
 
 
 
=====Endocrine=====
 
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
 
=====Metabolic and Nutritional=====
 
 
 
 
=====Musculoskeletal=====
 
 
 
 
=====Neurologic=====
 
 
 
 
=====Respiratory=====
 
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
 
=====Special Senses=====
 
 
 
 
=====Urogenital=====
 
 
 
 
=====Miscellaneous=====
 
 
 
<!--Postmarketing Experience-->
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
 
=====Body as a Whole=====
 
 
 
=====Cardiovascular=====
 
 
 
=====Digestive=====
 
 
 
=====Endocrine=====
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
=====Metabolic and Nutritional=====
 
 
 
=====Musculoskeletal=====
 
 
 
=====Neurologic=====
 
 
 
=====Respiratory=====
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
=====Special Senses=====
 
 
 
=====Urogenital=====
 
 
 
=====Miscellaneous=====
 
 
 
<!--Drug Interactions-->
|drugInteractions=* Drug
:* Description
 
<!--Use in Specific Populations-->
|useInPregnancyFDA=* '''Pregnancy Category'''
|useInPregnancyFDA=* '''Pregnancy Category'''
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''


There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
|useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
|useInLaborDelivery=*There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
|useInNursing=There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
|useInNursing=*There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
|useInPed=There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
|useInPed=*There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
|useInGeri=There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
|useInGeri=*There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
|useInGender=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
|useInGender=*There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
|useInRace=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
|useInRace=*There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
|useInRenalImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
|useInRenalImpair=*There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
|useInHepaticImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
|useInHepaticImpair=*There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
|useInReproPotential=There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
|useInReproPotential=*There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
|useInImmunocomp=There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
|useInImmunocomp=*There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.


<!--Administration and Monitoring-->
<!--Administration and Monitoring-->
|administration=* Oral
|monitoring=*There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
 
* Intravenous
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
 
* Description


<!--IV Compatibility-->
<!--IV Compatibility-->
|IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
|IVCompat=*There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.


<!--Overdosage-->
<!--Overdosage-->
|overdose====Acute Overdose===
====Signs and Symptoms====
* Description
====Management====
* Description
===Chronic Overdose===
There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
<!--Pharmacology-->
<!--Drug box 2-->
|drugBox=[[File:Lansoprazole image.png|600px|thumbnail|left]]
|drugBox=[[File:Lansoprazole image.png|600px|thumbnail|left]]
{{clear}}
{{clear}}
Line 377: Line 198:


<!--Pharmacodynamics-->
<!--Pharmacodynamics-->
|PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
|PD=*There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.


<!--Pharmacokinetics-->
<!--Pharmacokinetics-->
|PK=There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
|PK=*There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.


<!--Nonclinical Toxicology-->
<!--Nonclinical Toxicology-->
|nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
|nonClinToxic=*There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.


<!--Clinical Studies-->
<!--Clinical Studies-->
|clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
|clinicalStudies=*There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.


<!--How Supplied-->
<!--How Supplied-->
Line 392: Line 213:


<!--Patient Counseling Information-->
<!--Patient Counseling Information-->
|drugImages=
|packLabel=[[File:Lansoprazole pdp.png|600px|thumbnail|left]]
|packLabel=[[File:Lansoprazole pdp.png|600px|thumbnail|left]]
{{clear}}
{{clear}}
Line 399: Line 218:
[[File:Lansoprazole label.png|600px|thumbnail|left]]
[[File:Lansoprazole label.png|600px|thumbnail|left]]
{{clear}}
{{clear}}
|fdaPatientInfo=adults 18 years of age and older  
|fdaPatientInfo='''Adults 18 years of age and older'''
    this product is to be used once a day (every 24 hours), every day for 14 days  
*this product is to be used once a day (every 24 hours), every day for 14 days  
    it may take 1 to 4 days for full effect, although some people get complete relief of symptoms within 24 hours  
*it may take 1 to 4 days for full effect, although some people get complete relief of symptoms within 24 hours  
 
[[File:Lansoprazole medication guide.png|600px|thumbnail|left]]
{{clear}}


14-Day Course of Treatment
'''14-Day Course of Treatment'''


    swallow 1 capsule with a glass of water before eating in the morning  
*swallow 1 capsule with a glass of water before eating in the morning  
    take every day for 14 days  
*take every day for 14 days  
    do not take more than 1 capsule a day  
*do not take more than 1 capsule a day  
    swallow whole. Do not crush or chew capsules.  
*swallow whole. Do not crush or chew capsules.  
    do not use for more than 14 days unless directed by your doctor  
*do not use for more than 14 days unless directed by your doctor  


Repeated 14-Day Courses (if needed)
Repeated 14-Day Courses (if needed)


    you may repeat a 14-day course every 4 months  
*you may repeat a 14-day course every 4 months  
    do not take for more than 14 days or more often than every 4 months unless directed by a doctor  
*do not take for more than 14 days or more often than every 4 months unless directed by a doctor  
    children under 18 years of age: ask a doctor before use. Heartburn in children may sometimes be caused by a serious condition.  
*children under 18 years of age: ask a doctor before use. Heartburn in children may sometimes be caused by a serious condition.  


Other information
Other information


    read the directions, warnings and package insert before use  
*read the directions, warnings and package insert before use  
    keep the carton and package insert. They contain important information.  
*keep the carton and package insert. They contain important information.  
    store at 20-25°C (68-77°F)  
*store at 20-25°C (68-77°F)  
    keep product out of high heat and humidity  
*keep product out of high heat and humidity  
    protect product from moisture
*protect product from moisture
 
[[File:Lansoprazole medication guide.png|600px|thumbnail|left]]
{{clear}}
|alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
|alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.


<!--Brand Names-->
<!--Brand Names-->
|brandNames=* ®<ref>{{Cite web | title =  | url =  }}</ref>
|brandNames=Prevacid,
 
Prevacid I.V.,
<!--Look-Alike Drug Names-->
Prevacid SoluTab,
First - Lansoprazole
|lookAlike=* A® — B®<ref name="www.ismp.org">{{Cite web  | last =  | first =  | title = http://www.ismp.org | url = http://www.ismp.org | publisher =  | date =  }}</ref>
|lookAlike=* A® — B®<ref name="www.ismp.org">{{Cite web  | last =  | first =  | title = http://www.ismp.org | url = http://www.ismp.org | publisher =  | date =  }}</ref>


Latest revision as of 21:06, 20 October 2014

Lansoprazole
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Deepika Beereddy, MBBS [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Lansoprazole is a gastrointestinal, anti-ulcer agent that is FDA approved for the treatment of duodenal ulcer disease, erosive esophagitis, erosive esophagitis- maintanance, short-term treatment of active gastric ulcer, gastric ulcer - NSAID-associated gastropathy, gastroesophageal reflux disease, Zollinger-Ellison syndrome and for prophylaxis of gastric ulcer. Common adverse reactions include abdominal pain, constipation, diarrhea, nausea, headache.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Duodenal ulcer disease, Dual therapy - Helicobacter pylori gastrointestinal tract infection, Dual therapy
  • Dosing Information
  • Helicobacter pylori gastrointestinal tract infection, Dual therapy: dual therapy is not recommended due to the increasing resistance rates in Helicobacter pylori infections
Duodenal ulcer disease, Short-term treatment of active disease and maintenance of healed ulcers
  • Dosing Information
  • Treatment of active ulcer, 15 mg ORALLY once daily up to 4 weeks
  • Maintenance of healed ulcer, 15 mg ORALLY once daily
Duodenal ulcer disease, Triple therapy - Helicobacter pylori gastrointestinal tract infection, Triple therapy
  • Dosing Information
  • 30 mg ORALLY twice daily in combination with amoxicillin 1 gram ORALLY twice daily and clarithromycin 500 mg ORALLY twice daily for 10 to 14 days
  • 30 mg ORALLY twice daily in combination with metronidazole 500 mg ORALLY twice daily and clarithromycin 500 mg ORALLY twice daily for 10 to 14 days
Erosive esophagitis
  • Dosing Information
  • 30 mg ORALLY once daily for 8 to 16 weeks; another 8 weeks for recurrence may be considered
Erosive esophagitis, Maintenance
  • Dosing Information
  • 15 mg ORALLY once daily
Gastric ulcer, short-term treatment of active ulcer
  • Dosing Information
  • 30 mg ORALLY once daily up to 8 weeks
Gastric ulcer; Prophylaxis - NSAID-associated gastropathy
  • Dosing Information
  • 15 mg ORALLY once daily up to 12 weeks
Gastric ulcer - NSAID-associated gastropathy, Treatment
  • Dosing Information
  • 30 mg ORALLY once daily for 8 weeks
Gastroesophageal reflux disease
  • Dosing Information
  • 15 mg ORALLY once daily up to 8 weeks
Zollinger-Ellison syndrome
  • Dosing Information
  • 60 mg ORALLY once daily up to 90 mg twice daily

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Lansoprazole in adult patients.

Non–Guideline-Supported Use

Duodenal ulcer disease, Quadruple therapy - Helicobacter pylori gastrointestinal tract infection, Quadruple therapy
  • Dosing Information
  • Helicobacter pylori gastrointestinal tract infection, Quadruple therapy: (quadruple therapy) lansoprazole 30 mg ORALLY twice daily, metronidazole 250 mg ORALLY four times a day, bismuth subsalicylate 525 mg ORALLY four times a day and tetracycline 500 mg ORALLY four times a day for 10 to 14 days
Gastric ulcer, Maintenance

Heartburn

  • Dosing Information
  • 15 mg ORALLY once a day for 14 days

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Erosive esophagitis(1 yr and older)
  • Dosing Information
  • 1 to 11 years of age, weight 30 kg or less, 15 mg ORALLY once daily for up to 12 weeks, may increase dose up to 30 mg twice daily if symptoms persist after 2 or more weeks of treatment
  • 1 to 11 years of age, weight more than 30 kg, 30 mg ORALLY once daily for up to 12 weeks, may increase dose up to 30 mg twice daily if symptoms persist after 2 or more weeks of treatment
  • 12 years of age and older, 30 mg ORALLY once daily for up to 8 weeks
Gastroesophageal reflux disease ( 1 year and older (oral formulation))
    • Dosing Information
  • 1 to 11 years of age, weight greater than 30 kg, 30 mg ORALLY once daily for up to 12 wk, may increase dose up to 30 mg twice daily if symptoms persist after 2 or more weeks of treatment
  • 12 years of age and older, 15 mg once daily for up to 8 weeks

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Lansoprazole in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Lansoprazole in pediatric patients.

Contraindications

  • Condition1

Warnings

Allergy alert: Do not use if you are allergic to lansoprazole

Do not use

  • if you have trouble or pain swallowing food, vomiting with blood, or bloody or black stools. These may be signs of a serious condition. See your doctor.

Ask a doctor before use if you have

  • liver disease
  • had heartburn over 3 months. This may be a sign of a more serious condition.
  • heartburn with lightheadedness, sweating or dizziness
  • chest pain or shoulder pain with shortness of breath; sweating; pain spreading to arms, neck or shoulders; or lightheadedness
  • frequent chest pain
  • frequent wheezing, particularly with heartburn
  • unexplained weight loss
  • nausea or vomiting
  • stomach pain

Ask a doctor or pharmacist before use if you are taking

  • warfarin (blood-thinning medicine)
  • prescription antifungal or anti-yeast medicines
  • digoxin (heart medicine)
  • theophylline (asthma medicine)
  • tacrolimus (immune system medicine)
  • atazanavir (medicine for HIV infection)

Stop use and ask a doctor if

  • your heartburn continues or worsens
  • you need to take this product for more than 14 days
  • you need to take more than 1 course of treatment every 4 months
  • you get diarrhea

If pregnant or breast-feeding,

  • ask a health professional before use.

Keep out of reach of children.

  • In case of overdose, get medical help or contact a Poison Control Center right away. (1-800-222-1222)

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Lansoprazole Clinical Trials Experience in the drug label.

Postmarketing Experience

There is limited information regarding Lansoprazole Postmarketing Experience in the drug label.

Drug Interactions

There is limited information regarding Lansoprazole Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • Pregnancy Category


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Lansoprazole in women who are pregnant.

Labor and Delivery

  • There is no FDA guidance on use of Lansoprazole during labor and delivery.

Nursing Mothers

  • There is no FDA guidance on the use of Lansoprazole with respect to nursing mothers.

Pediatric Use

  • There is no FDA guidance on the use of Lansoprazole with respect to pediatric patients.

Geriatic Use

  • There is no FDA guidance on the use of Lansoprazole with respect to geriatric patients.

Gender

  • There is no FDA guidance on the use of Lansoprazole with respect to specific gender populations.

Race

  • There is no FDA guidance on the use of Lansoprazole with respect to specific racial populations.

Renal Impairment

  • There is no FDA guidance on the use of Lansoprazole in patients with renal impairment.

Hepatic Impairment

  • There is no FDA guidance on the use of Lansoprazole in patients with hepatic impairment.

Females of Reproductive Potential and Males

  • There is no FDA guidance on the use of Lansoprazole in women of reproductive potentials and males.

Immunocompromised Patients

  • There is no FDA guidance one the use of Lansoprazole in patients who are immunocompromised.

Administration and Monitoring

Administration

There is limited information regarding Lansoprazole Administration in the drug label.

Monitoring

  • There is limited information regarding Monitoring of Lansoprazole in the drug label.

IV Compatibility

  • There is limited information regarding IV Compatibility of Lansoprazole in the drug label.

Overdosage

There is limited information regarding Lansoprazole overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

Mechanism of Action

Structure

File:Lansoprazole01.png
This image is provided by the National Library of Medicine.

Pharmacodynamics

  • There is limited information regarding Pharmacodynamics of Lansoprazole in the drug label.

Pharmacokinetics

  • There is limited information regarding Pharmacokinetics of Lansoprazole in the drug label.

Nonclinical Toxicology

  • There is limited information regarding Nonclinical Toxicology of Lansoprazole in the drug label.

Clinical Studies

  • There is limited information regarding Clinical Studies of Lansoprazole in the drug label.

How Supplied

Storage

There is limited information regarding Lansoprazole Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Lansoprazole |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Lansoprazole |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

Adults 18 years of age and older

  • this product is to be used once a day (every 24 hours), every day for 14 days
  • it may take 1 to 4 days for full effect, although some people get complete relief of symptoms within 24 hours

14-Day Course of Treatment

  • swallow 1 capsule with a glass of water before eating in the morning
  • take every day for 14 days
  • do not take more than 1 capsule a day
  • swallow whole. Do not crush or chew capsules.
  • do not use for more than 14 days unless directed by your doctor

Repeated 14-Day Courses (if needed)

  • you may repeat a 14-day course every 4 months
  • do not take for more than 14 days or more often than every 4 months unless directed by a doctor
  • children under 18 years of age: ask a doctor before use. Heartburn in children may sometimes be caused by a serious condition.

Other information

  • read the directions, warnings and package insert before use
  • keep the carton and package insert. They contain important information.
  • store at 20-25°C (68-77°F)
  • keep product out of high heat and humidity
  • protect product from moisture

Precautions with Alcohol

  • Alcohol-Lansoprazole interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Prevacid, Prevacid I.V., Prevacid SoluTab, First - Lansoprazole

Look-Alike Drug Names

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. ↑ "http://www.ismp.org". External link in |title= (help)

{{#subobject: 

 |Page Name=Lansoprazole
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject: 

 |Label Page=Lansoprazole
 |Label Name=Lansoprazole11.png

}}

{{#subobject: 

 |Label Page=Lansoprazole
 |Label Name=Lansoprazole11.png

}}

Retrieved from "https://www.wikidoc.org/index.php?title=Lansoprazole&oldid=1034024"